The ongoing phase I/II study with 40 patients is due to complete in May/June 2019. The last study patient is expected to undergo scheduled surgery…
Read More
The phase I/II study in patients with bladder cancer addresses the safety of our drug candidate Alpha1H and measures biomarkers of efficacy. The protocol is…